Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms (DMNtFUS)

March 13, 2024 updated by: John Allen, University of Arizona

Altering Default Mode Network Activity to Reduce Depressive Symptoms

Depression is a leading cause of disability worldwide, affecting roughly 21 million adults. Repetitive Negative Thought (RNT) has been identified as a potential maintaining factor in depression, such that those who exhibit higher degrees of RNT endorse greater symptoms. Research also suggests that the Default Mode Network (DMN), responsible for self-referential processing, plays an important role in depression wherein it has been linked to RNT. In depressed individuals, this network appears to be hyper-connected, or "too connected", within itself which, in turn, is thought to promote RNT.

Half of depressed individuals are treatment-resistant, creating a critical need to identify more effective interventions derived from a better mechanistic understanding of the development and maintenance of depression. Non-invasive Transcranial-Focused Ultrasound Stimulation (tFUS) is promising for the treatment of depression. tFUS directs a low-intensity (nonthermal) focused ultrasound beam that passes safely through the skull. Compared to other noninvasive neuromodulation approaches, tFUS can target deeper brain regions with high spatial precision.

The present study is an exploratory non-blinded single treatment study to investigate whether tFUS targeting a major hub of the DMN, the anterior-medial prefrontal cortex, can improve depression symptoms and reduce RNT. Twenty depressed individuals with high RNT (75th percentile) will complete up to eleven ultrasound sessions targeting the anterior medial prefrontal cortex, a hub of the brain's default mode network that has been found to be hyper-connected in depression. MRI scans will be obtained before the first and after the last ultrasound sessions. Based on previous literature, it is predicted that depression interview ratings and self-report symptoms will decrease after the intervention, and also that DMN connectivity will decrease following intervention.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Participants will first complete the online screening to identify those who may meet criteria of major depressive disorder and have high RNT. Those meeting these criteria will be contacted for a formal diagnostic interview, consisting of the consent process and a structured clinical interview using the DSM-5. Once deemed eligible, participants will complete baseline interviews, self-report surveys, and an MRI session. Then, they will complete up to three weeks of ultrasound treatment, wherein the first week consists of five ultrasound sessions. Upon completion of week one, participants will complete the same interview, self-report surveys, and MRI session. Participants' symptom improvement will be determined by whether they meet remission criteria, defined as a Beck Depression Inventory Score - II (BDI-II) of <13 and a Hamilton Depression Rating Scale (HDRS) score of <8. If remission criteria are not met, participants will continue ultrasound sessions for two more weeks, three sessions per week. Following completion, participants will complete a final interview, self-report surveys, and MRI session. In each treatment session, the ultrasound device will be placed on the participants' forehead with the aid of the customized headset co-localized to the participant's structural MR image. Each ultrasound treatment lasts ten minutes.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Tucson, Arizona, United States, 85721
        • University of Arizona

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants must be between the ages of 18-50
  • Participants must have normal or corrected vision (glasses, contacts, etc)
  • Must be proficient in English in order to read the consent form (Spanish speakers are included, as long as they are also proficient in English)
  • Must be right-handed
  • Upper 25% of distribution on perseverative thinking scores based on local norms (score ≥ 37)
  • Participants meeting DSM-5 criteria for current major depressive episode

Participants may be excluded from the MRI portion of the experiment if they are pregnant or are unsure if they may be pregnant or have any contraindications for MRI, including severe claustrophobia, non-MRI compatible cardiac pacemakers; implantable defibrillators; aneurysm clips; neural stimulators; artificial heart valves; ear implants; insulin pumps; drug infusion devices; IUDs; magnetic dental appliances; metal fragments or foreign objects in the eyes, skin or body; metal plates, screws, and prosthetics; non-removable metal piercings; tattoos on the head and neck, other certain older tattoos or permanent makeup (eyeliner) using metal-containing inks, some medicated patches, or any other condition, metal implant or other injury or device that is contraindicated for MRI. If a subject has any of these, the experimenter will evaluate whether it is safe for them to participate in the MRI portion of the experiment.

Exclusion Criteria:

  • History of head injury with loss of consciousness for more than 5 min
  • Uncorrected hearing or vision impairment severe enough to interfere with participation.
  • Currently have or history of brain or mental illness judged likely to interfere with testing, including drug and/or alcohol dependence
  • Sleep disorder (e.g., insomnia)
  • Current drug, alcohol, or prescription drug intoxication
  • History of epilepsy
  • History of diagnosed migraines
  • Metal implants in their head or face, including dental retainers that cannot be removed
  • History of cardiac problems that could impact brain function (e.g., atrial fibrillation)
  • Current active suicidal potential necessitating immediate treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Non-invasive Transcranial Focused Ultrasound

Device: Transcranial Ultrasound Power

The ultrasound will be delivered using a custom Neuromodulation device consisting of 128 element ultrasound array (Openwater) with the ultrasound beam having the following parameters: acoustic frequency = 400 kHz, pulse duration = 5 ms, pulse repetition rate (PRR) = 10 Hz, spatial peak/temporal average acoustic intensity = 435 mW /cm2, peak negative pressure 650 kPa. The ultrasound probe will be secured by a custom-designed headset created by Openwater. The Localite Neuronavigation Software (TMS Navigator 3.3 adapted for ultrasound device), including a 3D camera, fiducial markers on the headset and pointer, and software will register the position of the probe with respect to the patient's structural MRI.
Device: Non-Invasive Transcranial Focused Ultrasound
The ultrasound will be delivered for 10 minutes per treatment session targeting to the participant's amPFC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Beck Depression Inventory - II (BDI-II)
Time Frame: Before ultrasound treatment, daily after each ultrasound session, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
The BDI-II is one of the most widely used self-report measures for assessing depression. It includes 21 self-report items. Scores range from 0 to 63, and higher scores indicate higher levels of depressive symptoms. In this study, the BDI-II was used to monitor depressive symptoms over the course of treatment. In our research, we will employ the BDI-II to track changes in self-reported depressive symptoms throughout the intervention, comparing the total BDI-II scores at different assessment points to analyze the efficacy of the treatment.
Before ultrasound treatment, daily after each ultrasound session, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
Perseverative Thinking Questionnaire (PTQ)
Time Frame: Before ultrasound treatment, daily after each ultrasound session, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
The PTQ is a commonly used self-report measure for assessing a characteristic of depression, repetitive negative thought (RNT). It includes 15 self-report items. Scores range from 0 to 60, and higher scores indicate higher levels of RNT. In this study, the PTQ was used to monitor RNT over the course of treatment. In our research, we will employ the PTQ to track changes in RNT throughout the intervention, comparing the total PTQ scores at different assessment points to analyze the efficacy of the treatment.
Before ultrasound treatment, daily after each ultrasound session, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
Hamilton Depression Rating Scale (HDRS)
Time Frame: Before ultrasound treatment, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
The Hamilton Depression Rating Scale (HDRS) is a widely utilized clinician-administered assessment tool designed to measure the severity of depressive symptoms in individuals. Comprising 17 items, the HDRS evaluates various aspects of depression. Scores range from 0 to 52, and higher total scores indicate greater depressive symptoms. In our research, we will employ the HDRS to track changes in depressive symptoms throughout the intervention, comparing the total HDRS scores at each main time point to analyze the efficacy of the treatment.
Before ultrasound treatment, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
Default Mode Network (DMN) Connectivity
Time Frame: Before ultrasound treatment, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
The DMN is a set of brain regions known to be "hyperconnected" in depressed individuals and may be a potential biomarker for this costly disorder. In our research, we will compare DMN connectivity at each major time point to observe whether there is a decrease in DMN connectivity to assess the efficacy of treatment.
Before ultrasound treatment, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: Before ultrasound treatment, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)
The MADRS is a clinician-administered assessment tool commonly used to evaluate the severity of depressive symptoms in individuals. It consists of 10 items that assess various aspects of depression. Scores range from 0 to 60, with higher scores indicating more severe depressive symptoms. In our research, we will employ the MADRS to track changes in depressive symptoms throughout the intervention, comparing the total MADRS scores at each main time point to analyze the efficacy of the treatment.
Before ultrasound treatment, after completion of week 1 of treatment, after completion of week 3 of treatment (if applicable)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Arizona

Collaborators

Openwater

Investigators

  • Principal Investigator: John JB Allen, PhD, University of Arizona Psychology Department
  • Principal Investigator: Jessica N Schachtner, BA, University of Arizona Psychology Department

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 27, 2023

Primary Completion (Actual)

January 3, 2024

Study Completion (Estimated)

June 3, 2024

Study Registration Dates

First Submitted

March 13, 2024

First Submitted That Met QC Criteria

March 13, 2024

First Posted (Actual)

March 20, 2024

Study Record Updates

Last Update Posted (Actual)

March 20, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 019782-00001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Non-Invasive Transcranial Focused Ultrasound

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe